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Abstract
Epigenetic changes, including DNA methylation, are a
common finding in cancer. In lung cancers methylation
of cytosine residues may affect tumor initiation and
progression in several ways, including the silencing of
tumor suppressor genes through promoter methylation
and by providing the targets for adduct formation of
polycyclic aromatic hydrocarbons present in combus-
tion products of cigarette smoke. Although the impor-
tance of aberrant DNA methylation is well established,
the extent of DNAmethylation in lung cancers has never
been determined. Restriction landmark genomic scan-
ning (RLGS) is a highly reproducible two-dimensional
gel electrophoresis that allows the determination of the
methylation status of up to 2000 promoter sequences in
a single gel. We selected 1184 CpG islands for RLGS
analysis and determined their methylation status in 16
primary non–small cell lung cancers. Some tumors did
not show methylation whereas others showed up to
5.3% methylation in all CpG islands of the profile.
Cloning of 21 methylated loci identified 11 genes and 6
ESTs. We demonstrate that methylation is part of the
silencing process of BMP3B in primary tumors and lung
cancer cell lines. Neoplasia (2001) 3, 314–323.
Keywords: non– small cell lung cancer, DNA methylation, RLGS, genome scanning,
epigenetic.
Introduction
Lung cancer is the leading cause of cancer - related death in
both males and females worldwide [1] . Clinically, lung
cancer can be divided into two groups: small cell lung cancer
(SCLC) and non–small cell lung cancer (NSCLC) [2,3] .
The latter constitutes approximately 75% of all lung cancers
[2 ] and includes squamous cell carcinoma (SCC), adeno-
carcinoma (AC) and large cell carcinoma (LCC) (approx-
imately 30%, 40% and 15%, respectively in all lung cancer
cases in North America) [3] .
Molecular abnormalities in lung cancer affect both
growth-promoting oncogenes and growth- inhibiting tumor
suppressor genes. So far mutations have been reported in
the oncogene K-RAS [4–6] as well as in tumor
suppressor genes p53 [7 ] , CDKN2 [8–11] and RB
[12] . In addition to genetic changes, the epigenetic
change of DNA methylation, the addition of a methyl
group to the cytosine ring in 50 -CpG-30 dinucleotides, may
play a significant role during lung cancer development
[13–17] . DNA methylation is established and maintained
by a family of DNA methyltransferases [18] and affects
chromatin organization as well as gene expression [19] . A
well -studied example in lung cancer is the aberrant
promoter methylation of the tumor suppressor gene,
CDKN2, which correlates with gene silencing [8,10,20–
22] . Because most of the reports describe methylation in
single cancer genes, no measurement of the overall
contribution of promoter methylation in lung cancer exists.
As an initial step to address this question, Zochbauer-
Muller et al. showed that numerous genes, including
retinoic acid receptor  -2 (RAR ) , tissue inhibitor of
metaloproteinnase 3 (TIMP-3 ) , CDKN2, O6-methylgua-
nine-DNA-methyltransferase (MGMT ) , death-associated
protein kinase (DAPK ) , E-cadherin (ECAD ) , p14ARF and
glutathione S-transferase P1 (GSTP1 ) , were methylated
at various degrees in a collection of 107 primary NSCLC
[22] .
Methylation changes in lung cancer appear to be early
events and thus should be useful in improving early
detection of potentially malignant cells [23–25] . For
example, CDKN2 promoter methylation is proposed as a
biomarker for early detection of lung cancer and monitoring
of prevention trials [23–25] . Using sensitive PCR-based
methylation analysis, methylation in CDKN2 and/or MGMT
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promoters was found in sputum of smokers up to 3 years
before clinical diagnosis of squamous cell lung carcinoma
[23–25] .
There is a need for the identification of novel markers
in lung cancer as well as the identification of cancer -
related genes. Aberrantly methylated target sequences
can guide a search for novel genes that may be useful
biomarkers, as well as candidate cancer genes. In this
study we use, for the first time, restriction landmark
genomic scanning (RLGS) to determine frequencies of
DNA methylation and to identify novel methylation targets
in NSCLC samples. Transcription patterns for one
methylated gene, BMP3B, were studied in greater detail
in primary tumors as well as in lung cancer cell lines. We
show that aberrant methylation of the CpG island of
BMP3B downregulates gene transcription of this interest-
ing gene product.
Materials and Methods
Primary Human NSCLC Samples and Cell Lines
The tumor samples were derived from patients here at
The Ohio State University, James Cancer Hospital. Com-
plete pathologic classification is available for all tumor
samples studied. Tissues were collected through the
Cooperative Human Tissue Network to maintain patients’
confidentiality. Samples were subsequently stored in our
lung tumor tissue bank. Sixteen frozen paired NSCLC
tumors with normal adjacent tissue were selected for this
study. We used four lung cancer cell lines, all obtained from
ATCC. H23 was derived from an AC, H125 was derived from
an adenosquamous carcinoma, H522 was derived from an
AC, and H1115 was derived from an LCC that metastasized
to the lymph node. All cell lines were cultured in RPMI-1640
medium (Gibco BRL, Rockville, MD) supplemented with
10% fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml
streptomycin (Gibco BRL).
Two-Dimensional Separation by Restriction Landmark
Genome Scanning (RLGS)
RLGS was performed as described previously [26,27] . In
summary, high molecular weight DNA was digested with the
methylation sensitive restriction enzyme NotI (Promega,
Madison, WI) , end- labeled by [ - 32P]dGTP and
[ -32P]dCTP (Amersham, Piscataway, NJ) , and then
digested using the restriction enzyme EcoRV (Promega) .
NotI–EcoRV DNA fragments were separated in a first
dimension through a 0.8% agarose tube gel, followed by
an in-gel digestion with a third restriction enzyme, HinfI
(New England Biolabs, Beverly MA). Finally, the DNA was
separated on a second dimension 5% polyacrylamide gel;
the gel was dried and exposed to X-ray film for 5 to 10 days.
RLGS profiles of primary tumors and normal adjacent lung
tissue were superimposed to visually detect differences in
the intensities and/or presence of the radiolabeled frag-
ments.
RLGS Analysis
The fragments in the RLGS profiles have been named on
our ‘‘Master RLGS profile’’ (see website E-mail: http: / /
pandora.med.ohio-state.edu/masterRLGS/ ) . The master
RLGS profile, derived from normal peripheral blood
lymphocyte DNA, is divided into 63 sections. Each RLGS
fragment is given a unique identifier (e.g., 3C1) that relates
to the position within the RLGS profile. Therefore, data sets
from different patients can be compared to identify
commonly changed fragments.
Cloning of RLGS Fragments
A human NotI–EcoRV plasmid library and library mixing
gels were created previously to facilitate cloning of RLGS
fragments [26,28] . These mixing gels allow the determi-
nation of an address for a library clone corresponding to the
RLGS fragment by identifying enhancement in the plate, row,
and column mixing gels [26] . Bacterial clones were cultured
in LB medium with ampicillin to isolate plasmid DNA using
Qiagen miniprep kit (Qiagen, Valencia, CA) . The plasmid
DNA was digested with NotI and EcoRV (Promega) , end-
labeled with [ - 32P]dGTP and [ -32P]dCTP (Amer-
sham). Labeled DNA, 5.2 and 10.4 pg per clone, were
mixed with labeled peripheral blood lymphocytes (PBL)
genomic DNA from a normal healthy donor, and subse-
quently separated in the two-dimensional RLGS mixing gel.
Enhanced intensities of the RLGS fragment of interest in
these mixing gels indicated that the NotI /EcoRV clone
represents the RLGS fragment of interest.
Characterization of RLGS Fragments
The confirmed plasmid clones are sequenced with M13
forward and M13 reverse primers. DNA sequences from
M13 forward primer were used to perform standard
nucleotide–nucleotide BLAST searches, using nonredun-
dant (nr ) and high throughput genomic sequence (htgs)
databases at release time March 1, 2001 (http: / /
www.ncbi.nlm.nih.gov/BLAST/ ) . When possible, 2-kb
genomic sequences from both sides of the NotI site were
used for subsequent BLAST searches for genes or ESTs.
Chromosomal location of cloned DNA fragments were
obtained either directly from the information given in
Genebank (http: / /www.ncbi.nlm.nih.gov/ ) , or by searching
the OMIM database (http: / /www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=OMIM) using gene names, or by searching
the BAC resource website (http: / /www.ncbi.nlm.nih.gov /
genome/cyto/hbrc.shtml ) that contains cytogenetic data of
FISH-mapped and sequence- tagged BAC clones. The
properties of CpG islands were determined using a web-
based program http: / /www.itba.mi.cnr.it /webgene/ , which
is provided by the Institute of Advanced Biomedical
Technologies ( ITBA), Italy.
Southern Hybridization
Southern hybridization was performed as described
previously [26] . Briefly, control samples, DNA from healthy
donors, were digested by EcoRV alone and a NotI /EcoRV
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combination. The control sample will show the expected
fragment size in the EcoRV digestion and a smaller fragment
in the double digestion. All tumor samples were digested by
NotI /EcoRV. The probes were prepared by restriction
enzyme digestion of the clone DNA, purification of the target
fragments, and subsequent labeling by random priming
using the Prime IT II kit (Stratagene, La Jolla, CA).
Percentage of methylation was quantified by a phosphor-
imager.
5-aza-2 0 -Deoxycytidine Treatment of Cell Lines
A total of 3106 cells of each NSCLC cell line were
seeded into T75 culture flasks and cultured with RPMI-1640
media overnight. 5-aza-20 -deoxycytidine media was freshly
made each day from stock solution (10 mmol / l in 100%
DMSO) (Sigma, St. Louis, MO) to a final concentration of 1
mol/ l. Cells were cultured with 5-aza-20 -deoxycytidine
medium for 24 hours and then washed with PBS twice and
continued to culture with fresh medium without 5-aza-20 -
deoxycytidine for 2 days (24-hour timepoint ) . Cells for the
72-hour timepoint were cultured in 5-aza-20 -deoxycytidine
medium that was changed daily for 3 days, then washed with
PBS twice and continued to culture in fresh medium without
5-aza-20 -deoxycytidine for one additional day.
Semiquantitative RT-PCR
Total RNA from cell lines with or without 5-aza-20 -
deoxycytidine treatment, primary tumors and paired normal
adjacent lung tissue was isolated using TRIzol (Gibco BRL)
and purified by RNeasy Mini Kit (Qiagen) . Three micro-
grams total RNA was reverse transcribed in vitro by random
hexamer and oligo dT using SUPERSCRIPT first -strand
synthesis kit (Gibco BRL) . cDNA was amplified by PCR.
Primers for RT-PCR were designed from the published
cDNA sequences. Forward and reverse primers are from
different exons to avoid amplification from genomic DNA.
Primer sequences were as follows: BMP3B forward: 50 -
GGTGGACTTCGCAGACATCG-30; BMP3B reverse: 50 -
GATGGTGGCATGGTTGGATG-30, product size: 130 bp.
GPI forward: 50 -GACCCCCAGTTCCAGAAGCTG-30; GPI
reverse: 50 -GCATCACGTCCTCCGTCACC-30, product
size: 178 bp. In all reactions the forward primer for each
pairs was end labeled by [ -32P]ATP with T4 kinase (Gibco
BRL).
The semiquantitative radioactive RT-PCRwas performed
with optimized conditions for both the target gene and an
internal control, glucose-6-phosphate isomerase (GPI ) , in
a single reaction tube. Amplification was stopped in the
exponential range for both genes. The exponential range
was determined by phosphorimager quantification of the
PCR product band intensities from different amplification
cycles. Each PCR reaction was carried out in 50 l final
volume containing 5 l of 10 PCR buffer, 1.5 mMMgCl2, 10
pmol of each primer, 200 M of each dNTP and 2.5 U
Platinum Taq DNA polymerase (Gibco) . The reactions were
initiated with 958C for 10 minutes to activate DNA polymer-
ase and then followed by amplification. BMP3B was
amplified at 968C for 20 seconds, 638C for 15 seconds,
and 728C for 15 seconds for eight cycles before addition of
GPI primers and additional 22 cycles.
Statistical Methods
Tests were performed for heterogeneity in methylation
across patients and for preferential methylation of certain
CpG island fragments, described in detail in Ref. [30] .
Briefly, the heterogeneity test is based on a comparison of
the mean methylation frequency to its variance in a chi -
square statistic. Preferential methylation is assessed using a
standard goodness-of - fit test [29] assuming that all spots
are lost at equal true frequency. Empirical null distributions
for both of these statistics were obtained by performing
appropriate 10,000 random permutations of the fragment /
patient data. Such an approach accounts for multiple testing
( i.e., multiple fragments were examined) and does not rely
on asymptotic distribution assumptions.
Results
Levels of Methylation in CpG Islands of NSCLC
RLGS profiles from 16 matched pairs consisting of lung
tumors from NSCLC patients and matched normal lung
tissue were prepared using the enzyme combination NotI–
EcoRV–HinfI (Figure 1A ) . Each tumor profile was com-
pared against the matching normal lung RLGS profile.
Previously, we had shown that the loss of an RLGS fragment
in the tumor compared with the matching normal is indicative
of DNAmethylation in theNotI site [30,31] . The total number
of methylation events out of 1184 RLGS fragments analyzed,
as well as clinical data for the patients are shown in Table 1.
The range of methylation in these samples is from 0% to
5.3%. Although most (12 of 16) of the tumor samples
showed methylation levels below 1%, 4 of 16 patients show
levels of CpG island methylation above 2%. Of these,
patients 5, 11, 14, and 17 show methylation frequencies of
4.9%, 5.3%, 2.4%, and 5.0%, respectively. No obvious
correlation of overall methylation frequency and clinical data
can be seen. This range of variation is greater than would be
expected if all patients had the same underlying methylation
rate. A chi -square test (see Statistical Methods section)
shows significant heterogeneity in methylation levels across
the patients (P<.0001) . In addition, some CpG islands are
preferentially methylated, as indicated by the number of
fragments showing relatively high methylation frequency
(Figure 2, P<.0001) . Of the total 1184 analyzed RLGS
fragments, 1036 were never methylated. A total of 76
fragments were methylated in only one tumor, 53 fragments
were methylated in two tumors, 9 fragments (2E61, 2F43,
3D24, 3F82, 3F85, 4D8, 4E53, 4F15, and 4F58) were
methylated in three tumors, 2 fragments (2D45 and 3F16)
were methylated in four tumors, 1 fragment (3F28) was
methylated in five tumors, 1 fragment (3G78) was methy-
lated in seven tumors, 5 fragments (2C35, 3C1, 3E55, 4E1,
and 1 RLGS fragment not present in the RLGS master
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profile ) were methylated in eight tumors, and 1 fragment
(1F22) was methylated in nine tumor samples (Figure 2 ) .
No correlation between global methylation frequency and
any of the clinical parameters including tumor stage, differ-
entiation, histopathological classification, age or gender
could be detected. However, it is interesting to note that a
subset of methylation events correlate with the histopatho-
logical features of the tumors. For example, of the 50 CpG
island sequences that are methylated at least twice in tumors
with clear histopathology (excluding patients No. 3, 10, and
15) , 1 is found only in the two LCCs, no CpG islands was
found methylated only in the four ACs, and 2 are found
1B.
Normal lung Lung cancer Mixing gel
4F15 4F15 4F15
3C1 3C13C1
1D
2D
0.55
4.4 kb3.01.20.45
1.40
0.35
0.16
1A. 1C.
RV
N/RV
M PBL N  T   N   T   N  T   N   T   N   T  N   T
P5     P6    P14   P18   P11 P17
RV
N/RV
Cell lines
H1
15
5
H5
22
H1
25
H2
3
PB
L
PB
L
1D.
PBL N   T  N   T   N   T   N  T    T N  T  N
N/RV
P5      P6      P14 P18    P11  P17
Primary tumors
RV
Figure 1. RLGS and confirmation of methylation by Southern hybridization. (A ) Representative RLGS profile of normal lung DNA using the enzyme combination
NotI –EcoRV–HinfI. Fragment sizes for the first dimension ( 1D ) and second dimension ( 2D ) are given in kilobases. (B ) Sections of RLGS profiles from normal lung
and lung tumor from patient 17 highlighting RLGS fragment 3C1 (GNAL ) and 4F15 (BMP3B ) ( arrows ). While the lung cancer profile shows decreased intensity of
3C1 and 4F15, the mixing gel shows enhancement, indicating that the correct NotI –EcoRV clone was isolated from the library. Only differences in RLGS fragments
3C1 and 4F15 were indicated, other changes between normal and tumor profiles were not marked by arrows. (C ) and (D ) Southern blot analysis of primary lung
cancers and matched normal adjacent tissue. Hybridization was used to confirm methylation of RLGS fragment 3C1, GNAL (C ) and 4F15, BMP3B (D ) in RLGS
profiles of primary lung cancer is due to DNAmethylation. The peripheral blood lymphocyte (PBL ) DNA in the first lane of each blot was digested with EcoRV only. All
other tumor (T ) and normal adjacent lung (N ) DNA samples were double digested by EcoRV/NotI. The majority of the DNA is digested by NotI and results in the
smaller NotI –EcoRV (N /RV ) fragment. Tumor samples show amuch higher degree of methylation. M: indicates the marker lane. H23, H125, H522, and H1155 are
lung cancer cell lines.
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methylated exclusively in the seven SCCs. Other methyl-
ation events (a total of 16 CpG islands) are shared between
all three subtypes. In addition seven methylation events are
found in AC and LCC, nine are shared between AC and SCC
and a total of 15 CpG islands are methylated in both SCC
and LCC (Table 2) . Validation of thesemethylation events in
larger sample sets is required to unambiguously identify
tumor–type–specific methylation events.
Cloning of RLGS Fragments and Properties of Cloned
Fragments
To further characterize some of the methylated fragments
in NSCLC, the NotI /EcoRV plasmid clone library mixing gels
were used to locate the corresponding clones [26] . Clones
with expected insert sizes were analyzed in RLGS mixing
gels to confirm that the correct fragment was cloned. Figure
1B shows two examples for RLGS fragments 3C1 and 4F15.
A total of 21 fragments were cloned and sequenced. Twelve
of these clones (2D14, 2D20, 2C35, 2E24, 2E61, 3B36,
3C1, 3E55, 3F16, 3F50, 3F82, and 4E53) have been
identified as methylation targets in other types of malignan-
cies [30–32] . BLAST searches identified homologies to 11
genes and six EST sequences (Table 3) . Two sequences
(3F16 and 3F82) show high homology to DNA-binding
protein A (DBPA ) and mouse early B-cell factor 3,
respectively and may represent either pseudogenes or novel
gene family members. The remaining two showed homology
to genomic sequences. We found that 20 of 21 NotI sites are
located within CpG islands. Six of the 11 CpG islands with
homology to genes are located in the 50 end of the genes.
The CpG islands identified in insulin promoter factor 1
( IPF1 ) , orthodenticle (drosophila ) homolog 1 (OTX1 ) ,
HOX11, T-box brain 1, monocarboxylate transporter 3
(MCT3 ) are located in the middle or 30 end of the genes.
Chromosomal location of all the fragments were derived from
database searches of the human draft sequence of the
human genome, Genebank or OMIM database. The detailed
information for these 21 fragments, including fragment
addresses on master profile, total methylation frequency in
primary tumors, CpG island properties and location in the
Table 1. DNA Methylation in 16 Patients with Lung Cancer.
Patient
No.
Methylation events out
of 1184 CpG islands
% Methylation Age Gender Tumor
stage
Differentiation Tumor
type
1 5 0.4 45 F T2N1, IIB Well AC
2 3 0.3 72 M T1N0, IA Moderate SCC
3 7 0.6 56 F T2N1, IIB Poor LCC with features of AC
5 58 4.9 75 M T2N0, IB Moderate SCC
6 7 0.6 62 F T1N0, IA Poor SCC
7 2 0.2 68 M T3N2, IIIA Undifferentiated LCC
8 0 0 66 M T2N0, IB Well AC
9 5 0.4 78 F T1N0, IA Poor SCC
10 1 0.1 69 M T2N1, IIB Poor N /A
11 63 5.3 67 F T2N0, IB Poor LCC
13 0 0 76 M T1N1, IIA Poor SCC
14 28 2.4 61 M N/A Poor SCC
15 4 0.3 70 F T3N0, IIB N /A LCC with SCC and AC
16 2 0.2 79 F T1N0, IA N /A AC (with clear cell features )
17 59 5.0 81 M N/A Well AC
18 8 0.7 63 F N /A Poor SCC
SCC, squamous cell carcinoma; AC, adenocarcinoma; LCC, large cell carcinoma. N /A, no data available.
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Figure 2. Global methylation patterns in lung cancer are nonrandom.
Frequency distribution of methylation events in CpG islands within 16
NSCLCs.
Table 2. Distribution of CpG Islands Methylated at Least Twice in Various
Histopathological Subgroups of Non–Small Cell Lung Cancer.
Subgroup Number of methylated CpG islands
LCC 1
AC 0
SCC 2
LCC+AC 7
AC+SCC 9
LCC+SCC 15
LCC+AC+SCC 16
LCC, large cell carcinoma; AC, adenocarcinoma; SCC, squamous cell
carcinoma.
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genes, BLAST search results, and chromosomal location of
the genes, are listed in Table 3.
RLGS Fragment Loss Is Due to DNA Methylation
Southern hybridization was performed as a more sensi-
tive method to estimate the degree of methylation of the NotI
site from RLGS fragments lost in tumors. Southern hybrid-
ization has the ability to detect methylation as low as 5% to
10%, whereas RLGS allows the detection of 30% methyl-
ation [31] . Southern blot hybridization was also performed
to evaluate the possibility that the RLGS fragment loss was
due to homozygous deletion. Corresponding NotI /EcoRV
plasmid clones for four RLGS fragments were used as
probes on Southern blots. These four clones included three
fragments with homology to known genes 3C1 (G- -
olfactory, GNAL ) , 3E55 ( insulin promoter factor 1, IPF1 ) ,
and 4F15 (Bone morphogenetic protein 3B, BMP3B ) . In
addition, fragment 2C35 with homology to an EST sequence
was used. Representative Southern blots for RLGS fragment
3C1 (GNAL ) and 4F15 (BMP3B ) are shown in Figure
1C and D , respectively. Tumor samples and paired normal
adjacent lung tissue DNAs were digested with NotI /EcoRV.
The detection of a fragment in the NotI /EcoRV digests equal
in size to the one detected with EcoRV only was scored as a
methylation event in the tumor DNA. The hybridization
shows that most tumor samples have a much higher degree
of methylation of the NotI site than the normal counterparts.
Some of the normal tissue DNAs show a small fraction of
methylated sequences. These normal lung tissues were
matched controls derived from the lung cancer patients and it
is possible that they may contain contaminating preneo-
plastic cells. No homozygous deletions were detected
because the hybridization signals are present in all tumor
samples. Methylation of the NotI site in the 50 end of GNAL
was observed in 10 of 16 patients. Methylation of 4F15
(BMP3B ) , was detected in five of six tumors and thus
confirmed the methylation events found by RLGS. Tumor-
specific or increased methylation was observed in 11 of 16
primary NSCLC for fragment 2C35 and 11 of 16 for 3E55
( IPF1 ) (Figure 1C and D and data not shown).
Aberrant Transcription of BMP3B in Primary NSCLC and
NSCLC Cell Lines
Radioactive, semiquantitative RT-PCR reactions were
performed to determine the expression levels of BMP3B in
six primary NSCLC samples and their paired normal lung
tissue. BMP3B was found hypermethylated in a CpG island
that is located in the 50 end of the gene (Figure 3A ) and was
selected for further analysis. RT-PCR was performed under
optimized conditions for both the target gene and the internal
control gene glucose-6-phosphate isomerase (GPI ) .
BMP3B was expressed in normal lung, whereas expression
of BMP3B in all studied tumor samples was reduced (Figure
3B ) . Interestingly, tumors from patients Nos. 2 and 6, which
did not show methylation of the NotI site exhibited very low
levels of BMP3B expression, suggesting heterogeneous
methylation of the CpG island. However, it is also possible,
andmaybe evenmore likely, that BMP3B is silenced by other
mechanisms including mutations, deletions and/or LOH.
To investigate the effect of CpG island methylation on the
transcription of the associated genes in more detail, we used
three NSCLC cell lines that are methylated in the NotI site of
BMP3B promoter region. H23, H125, and H1155 show more
than 50% methylation in the BMP3B promoter. The cells
Table 3. Cloned RLGS Fragments Altered in RLGS Profiles of 16 Primary Tumors.
RLGS master
address
No. of tumors
methylated
Methylation found
in following subgroups
CpG
island
Location of CpG
island in gene
Gene or EST Accession
number
Chromosomal
location
2C35 8 AC /LCC/SCC Yes EST BG142595 AL139281, NT_024073.1 10p12
3C1 8 AC /LCC/SCC Yes 50 end GNAL U55180 18p11.21 - pter
3E55 8 AC /LCC/SCC Yes 30 end IPF1 NM 000209 13q12.1
3G78 7 AC /LCC/SCC Yes 50 end TAL1 AL135960 1p32
2D20 4 AC /LCC/SCC Yes middle OTX1 AB037501 2p13
3F16 4 AC /LCC/SCC Yes Homologous to EBF AL354950, NT_024100.1 10q26
3F50 4 LCC /SCC Yes 30 end HOX11 AJ009794 10q24
2E61 3 SCC Yes EST AJ230817 AL354000 17p11.2
3B55 3 LCC /SCC Yes 30 end T-box brain 1 XM_002531 2q23 -27
3F82 3 LCC /SCC Yes Homologous to DBPA M24069
4D8 3 AC /LCC/SCC No EST BF928282 AC012118, NT_010641.1 17q25.1
4E15 3 LCC /SCC Yes EST BE247619 AC003959 5q
4E53 3 AC /LCC/SCC Yes AL353195, NT_009829.1 13q12.2
4F15 3 LCC /SCC Yes 50 end BMP3B D49493, NT_008757.1 10q11.21 - 11.23
5E25 3 AC /LCC/SCC Yes Formin 2 like AL359918, NT_004771.1 1q44
2D14 2 AC /LCC Yes 50 end CD8 1 Chain S87068 2p12
3B36 2 AC /SCC Yes 50 end CYP1b1 XM_002576 2p21 -22
3D44 2 AC /SCC Yes AL355304, NT_019429.1 6q23.1 - 6q24.3
5C32 2 AC /SCC Yes 50 end CD34 M81938 1q32
2E24 1 AC Yes middle MCT3 AF132611 22q12.3 - 13.2
3E34 1 SCC Yes EST AI631157 AC000068 22q11.2
AC, adenocarcinoma; LCC, large cell carcinoma; SCC, squamous cell carcinoma.
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were treated with two different timepoints (24 and 72 hours)
of 5-aza-20 -deoxycytidine (Figure 3C ) . Similar to the
primary tumors, all three cell lines (H23, H125, H1155) did
not show any detectable level of BMP3B expression at
baseline. However, expression was induced after 5-aza-20 -
deoxycytidine treatment in all three cell lines (Figure 3C ) .
Discussion
The methylation scanning properties of RLGS have pre-
viously been used for the identification of imprinted genes in
the mouse genome [33,34] , as well as for the identification
of methylated sequences in various human malignancies
[30,31,35] but not lung cancer. Genome-wide scans for
methylated sequences in lung cancer have been performed
by two different strategies including the use of a methylated
DNA binding column [36] and arbitrarily primed PCR [37] .
However, these techniques either showed a bias for
methylated repetitive sequences or were limited in the
number of analyzed sequences. In contrast, RLGS, a highly
reproducible two-dimensional gel electrophoresis, is a
genome-wide scan of DNA methylation changes in CpG
islands. Established cloning protocols utilizing an arrayed
plasmid clone library facilitate the rapid identification of
genomic sequences corresponding to the methylated targets
[26,28] . RLGS is based on the digestion of genomic DNA
with the methylation sensitive restriction enzyme NotI, which
can only digest unmethylated genomic DNA and does not
rely on prior knowledge of the gene sequence [26,31,35] .
We have used RLGS to determine the contribution of CpG
island hypermethylation in NSCLC and to identify novel
methylation targets. Although the importance of DNA
methylation in lung tumor development had been demon-
strated in several reports [23,38–40] , the overall extent was
previously unknown. Under the assumption that all RLGS
fragments represent promoter sequences we are, for the first
time, able to demonstrate that up to 5.3% of all promoter
regions, or 1537 of the estimated total 29,000 CpG islands
[41,42] in the tumor genome could be methylated. The
variability in the range of methylation shows that NSCLC
represents a heterogeneous group not only with respect to
the genetic defects identified but also on the epigenetic level.
Promoter methylation in cancer- related genes is well
known in lung cancer and is correlated with gene silencing in
genes involved in cell cycle (CDKN2 ) [8–11] , apoptosis
(DAP ) [43] , metastasis H-cadherin [44] and (TIMP-3 )
[45] , differentiation (RAR ) [46] , DNA repair (MGMT )
[47] , and the recently identified candidate tumor suppressor
gene (RASSF1A ) with homology to the RAS family [38] . In
this study, we have identified 21 additional genomic loci
including 11 genes and six ESTs with aberrant CpG island
methylation in NSCLC. None of the cloned genes has been
reported to be methylated in lung cancer previously.
However, it is interesting to note that CpG island 3F16 is
approximately 200 kb away from MGMT ( located in
sequence contig NT_024100.1) . MGMT is a DNA repair
gene that was previously found to be methylated in 21% of
NSCLCs [22] . This finding would suggest a more regional
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Figure 3. Abnormal transcription of BMP3B NSCLC samples. (A ) Schematic representation of the genomic structure of BMP3B. The location of the NotI site relative
to exon 1 and the extent of the CpG island are displayed. The star indicates the NotI site identified by RLGS. (B ) Semiquantitative radioactive RT -PCR was used to
determine the relative expression levels of BMP3B in six patients with lung cancer. Relative expression levels of RNAs obtained from tumor (T ) and normal adjacent
lung (N ) were determined by comparing the intensities to the internal control, GPI. Negative control (  ) contains water. GPI: Glucose -6 - phosphate isomerase.
(C ) Radioactive semiquantitative RT -PCR was used to determine the relative expression of BMP3B levels in RNAs from three cell lines (H23, H125, and H1155 )
after treatment with 5 0 - aza -2 0 - deoxycytidine. The upper panel shows the RT-PCR results and the lower panel shows the relative expression levels of BMP3B
compared to the internal control GPI. Cell lines were treated with 1 mol / l 5 0 - aza - 2 0 - deoxycytidine for either 24 hours ( 24 ) or 72 hours (72 ) . Untreated control cell
lines (C ) were harvested in exponential growth phase. Y -axis gives the relative ratio of band intensity for the target gene /GPI quantified by phosphorimager.
Negative control (  ) contained water, positive control ( + ) was normal lung tissue (NL ) .
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effect of methylation, similar to aberrant methylation found in
chromosome 17p11.2 in the major breakpoint cluster region
for medulloblastomas [30] . Another interesting target
sequence is 4D8 located in chromosome 17q25.1. Chromo-
some 17q had previously been implicated with frequent
(42%) loss of heterozygosity in NSCLC [48] , suggesting
that both genetic and epigenetic mechanisms could be
involved in the silencing of a putative tumor suppressor gene
in this region. Other fragments are derived from chromo-
some segments in 1p (3G78), 5q (4E15) , 10q (3F50) , 13q
(3E55) 18p (3C1), and 22q (2E24) , all within regions for
which either LOH or homozygous deletions have been
reported in lung cancer [49,50] . Whether any of the newly
identified genes meet the expected criteria for tumor
suppressor genes remains to be determined and will be the
focus of future work.
We focused our studies on RLGS fragment 4F15, derived
from a CpG island in the promoter region of the BMP3B gene
and determined the relation of CpG island methylation to
transcription. BMP3B is located in chromosome 10q11.21–
11.23, a region that shows 20% to 30% LOH in NSCLCs and
51% LOH in SCLCs [51] (see online http: / /www.helsinki.fi /
lgl_www/LOSS/Respiratory.html ) and thus located in a
candidate tumor suppressor region. BMP3B is a member of
the transforming growth factor  (TGF- ) superfamily,
originally identified due to their osteoinductive capacity.
Members of this family are usually involved in the regulation
of cell growth/differentiation during development and were
shown to be dysregulated in various human malignancies.
Interestingly other members of the BMP family have been
shown to induce apoptosis during organ development [52–
54] . In addition, two BMP family members, BMP4 and
BMP2, have been shown to induce apoptosis in multiple
myeloma cell lines [55] or hematopoetic cells [56] ,
respectively. BMP2 was also shown to suppress the trans-
formed phenotype in the human lung carcinoma cell line
A549 [57] .
BMP3B is highly expressed in human adult lung, brain,
skeletal muscle, pancreas, and testis, an expression pattern
that distinguishes it from the closest family member BMP3
[58] . BMP3B knockout mice did not show any detectable
abnormalities, suggesting a redundant function with that of
other members of the TGF- family [59] . However, adult rat
lung tissue does not express BMP3B suggesting the
possibility of different functions of BMP3B in rodents and
humans [60] . We have shown that methylation in BMP3B is
correlated with transcriptional repression. The repression is
reversible by treatment with the demethylating agent 5-aza-
20deoxycytidine. Thus, our data suggest a causal relation-
ship between methylation of the BMP3B promoter and
transcriptional repression. We found BMP3B downregulated
in all NSCLC patient samples and cell lines, even in those
without methylation in the NotI site, suggesting that
methylation patterns in the CpG island are heterogeneous.
This assumption was confirmed by COBRA analysis testing
the methylation status in four BstUI (CGCG) restriction sites
in the promoter (Dai et al. unpublished) . Alternatively, other
mechanisms (e.g., LOH or mutations) of gene silencing
could be present. Additional work to study the complete
genetic and epigenetic mutation spectrum of BMP3B in lung
tumorigenesis is underway.
The identification of multiple targets for methylation opens
the exciting possibility to use these methylation events as
biomarkers for the early detection of lung cancer in sputum
as demonstrated by others [23] . In addition, our data also
indicate the possibility that certain methylation events may
be specific for lung cancer or subtypes within this group and
thus could serve as potential markers for the molecular
classification of lung cancers and different disease stages.
Validation of methylation events as possible markers for
early diagnosis, as predictive markers for survival or markers
that classify subtypes will require larger sets of patient
samples.
Acknowledgements
We thank Julia Hall and Yue-Zhong Wu for expert technical
assistance. The authors thank Ming You for helpful advice
with the manuscript. Tissue samples were provided by the
Comparative Human Tissue Network (CHTN), which is
funded by the National Cancer Institute.
References
[1] Parkin DM, Pisani P, and Ferlay J ( 1999 ) . Global cancer statistics.
Ca-Cancer J Clin 49, 33–64.
[2] Marby M, Nelkin BD, and Baylin SB (1998 ) . Chapter 41 Lung cancer.
In The Genetic Basis of Human Cancer. B Vogelstein and KW Kinzler
(Eds ) . McGraw -Hill, New York, NY. pp. 671–679.
[3] Ginsberg RJ, Vokes EE, and Raben A (1997 ) . Section 2: Non–small
cell lung cancer in chapter 30: cancer of the lung. In Cancer: Principles
and Practice of Oncology. VT DeVita, Jr., S Hellman and SA
Rosenberg (Eds ) . Lippincott -Raven, Philadelphia, PA. pp. 858–865.
[4] Sekido Y, Fong KM, and Minna JD (1998 ) . Progress in understanding
the molecular pathogenesis of human lung cancer. Biochim Biophys
Acta 1378, F21–F59.
[5] Slebos RJ, and Rodenhuis S (1992 ) . The ras gene family in human
non–small - cell lung cancer. J Natl Cancer Inst Monogr 13, 23–29.
[6] Salgia R, and Skarin AT (1998 ) . Molecular abnormalities in lung
cancer. J Clin Oncol 16, 1207–1217.
[7] Chiba I, Takahashi T, Nau MM, D’Amico D, Curiel DT, Mitsudomi T,
Buchhagen DL, Carbone D, Piantadosi S, Koga H, et al. ( 1990 ) .
Mutations in the p53 gene are frequent in primary, resected non–small
cell lung cancer. Oncogene 5, 1603–1610.
[8] Otterson GA, Khleif SN, Chen W, Coxon AB, and Kaye FJ (1995 ) .
CDKN2 gene silencing in lung cancer by DNA hypermethylation and
kinetics of p16INK4 protein induction by 5 - aza 20deoxycytidine.
Oncogene 11, 1211–1216.
[9] Otterson GA, Kratzke RA, Coxon A, Kim YW, and Kaye FJ (1994 ) .
Absence of p16INK4 protein is restricted to the subset of lung cancer
lines that retains wildtype RB. Oncogene 9, 3375–3378.
[10] Gazzeri S, Gouyer V, Vour’ch C, Brambilla C, and Brambilla E (1998 ) .
Mechanisms of p16INK4A inactivation in non small - cell lung cancers.
Oncogene 16, 497–504.
[11] Kashiwabara K, Oyama T, Sano T, Fukuda T, and Nakajima T (1998 ) .
Correlation between methylation status of the p16 /CDKN2 gene and
the expression of p16 and Rb proteins in primary non–small cell lung
cancers. Int J Cancer 79, 215–220.
[12] Xu HJ, Hu SX, Cagle PT, Moore GE, and Benedict WF (1991 ) .
Absence of retinoblastoma protein expression in primary non–small
cell lung carcinomas. Cancer Res 51, 2735–2739.
[13] Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa JP (1998 ) .
Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv
Cancer Res 72, 141–196.
[14] Baylin SB, and Herman JG ( 2000 ) . DNA hypermethylation in
tumorigenesis: epigenetics joins genetics. Trends Genet 16, 168–174.
Neoplasia . Vol. 3, No. 4, 2001
Aberrant Methylation in Non-Small Cell Lung Cancer Dai et al. 321
[15] Robertson KD, and Jones PA (2000 ) . DNA methylation: past, present
and future directions. Carcinogenesis 21, 461–467.
[16] Tycko B (2000 ) . Epigenetic gene silencing in cancer. J Clin Invest 105,
401–407.
[17] Warnecke PM, and Bestor TH (2000 ) . Cytosine methylation and
human cancer. Curr Opin Oncol 12, 68–73.
[18] Bird A (1999 ) . DNA methylation de novo. Science 286, 2287–2288.
[19] Bird AP, and Wolffe AP (1999 ) . Methylation - induced repression -
belts, braces, and chromatin. Cell 99, 451–454.
[20] Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin
SB, and Sidransky D (1995 ) . 50 CpG island methylation is associated
with transcriptional silencing of the tumour suppressor p16 /CDKN2 /
MTS1 in human cancers. Nat Med 1, 686–692.
[21] Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, and Herman JG (1999 ) .
In situ detection of the hypermethylation - induced inactivation of the
p16 gene as an early event in oncogenesis. Proc Natl Acad Sci USA 96,
12754–12759.
[22] Zochbauer -Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, and
Minna JD (2001 ) . Aberrant promoter methylation of multiple genes in
non–small cell lung cancers. Cancer Res 61, 249–255.
[23] Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G,
Gabrielson E, Baylin SB, and Herman JG (1998 ) . Aberrant methyla-
tion of p16 ( INK4a ) is an early event in lung cancer and a potential
biomarker for early diagnosis. Proc Natl Acad Sci USA 95, 11891–
11896.
[24] Kersting M, Friedl C, Kraus A, Behn M, Pankow W, and Schuermann M
(2000 ) . Differential frequencies of p16 ( INK4a ) promoter hypermethy-
lation, p53 mutation, and K- ras mutation in exfoliative material mark the
development of lung cancer in symptomatic chronic smokers. J Clin
Oncol 18, 3221–3229.
[25] Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB,
Herman JG, and Belinsky SA (2000 ) . Predicting lung cancer by
detecting aberrant promoter methylation in sputum. Cancer Res 60,
5954–5958.
[26] Smiraglia DJ, Fru¨hwald MC, Costello JF, McCormick SP, Dai Z,
Peltomaki P, MS Od, Cavenee WK, and Plass C (1999 ) . A new tool for
the rapid cloning of amplified and hypermethylated human DNA
sequences from restriction landmark genome scanning gels. Genomics
58, 254–262.
[27] Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, and Mukai T
(1991 ) . A genomic scanning method for higher organisms using
restriction sites as landmarks. Proc Natl Acad Sci USA 88, 9523–9527.
[28] Plass C, Weichenhan D, Catanese J, Costello JF, Yu F, Yu L, Smiraglia
D, Cavenee WK, Caligiuri MA, deJong P, and Held WA (1997 ) . An
arrayed human NotI –EcoRV boundary library as a tool for RLGS spot
analysis. DNA Res 4, 253–255.
[29] Freund RJ, and Wilson WJ (1997 ) . Statistical Methods. Academic
Press, San Diego, CA.
[30] Fru¨hwald MC, O’Dorisio MS, Dai Z, Rush LJ, Krahe R, Smiraglia DJ,
Pietsch T, Elsea SH, and Plass C (2001 ) . Aberrant hypermethylation
of the major breakpoint cluster region in 17p11.2 in medulloblastomas
but not supratentorial PNETs. Genes Chromosomes Cancer 30, 38–
47.
[31] Costello JF, Fru¨hwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao
X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L,
Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H,
Petrelli NJ, Zhang X, MS OD, Held WA, Cavenee WK, and Plass C
( 2000 ) . Aberrant CpG - island methylation has non - random and
tumour - type–specific patterns. Nat Genet 24, 132–138.
[32] Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Fruhwald MF, Costello
JF, Held WA, Yu L, Krahe R, Kolitz JE, Bloomfield CD, Caligiuri MA,
and Plass C (2001 ) . Novel methylation targets in de novo acute
myeloid leukemia with prevalence of chromosome 11 loci. Blood 17,
3226–3233.
[33] Plass C, Shibata H, Kalcheva I, Mullins L, Kotelevtseva N, Mullins J,
Kato R, Sasaki H, Hirotsune S, Okazaki Y, Held WA, Hayashizaki Y,
and Chapman VM (1996 ) . Identification of Grf1 on mouse chromo-
some 9 as an imprinted gene by RLGS-M. Nat Genet 14, 106–109.
[34] Hayashizaki Y, Shibata H, Hirotsune S, Sugino H, Okazaki Y, Sasaki N,
Hirose K, Imoto H, Okuizumi H, Muramatsu M, and et al. ( 1994 ) .
Identification of an imprinted U2af binding protein related sequence on
mouse chromosome 11 using the RLGS method. Nat Genet 6, 33–40.
[35] Plass C, Yu F, Yu L, Strout MP, El -Rifai W, Elonen E, Knuutila S,
Marcucci G, Young DC, Held WA, Bloomfield CD, and Caligiuri MA
(1999 ) . Restriction landmark genome scanning for aberrant methyla-
tion in primary refractory and relapsed acute myeloid leukemia;
involvement of the WIT -1 gene. Oncogene 18, 3159–3165.
[36] Shiraishi M, Chuu YH, and Sekiya T (1999 ) . Isolation of DNA
fragments associated with methylated CpG islands in human adeno-
carcinomas of the lung using a methylated DNA binding column and
denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 96,
2913–2918.
[37] Kohno T, Kawanishi M, Inazawa J, and Yokota J ( 1998 ) . Identification
of CpG islands hypermethylated in human lung cancer by the arbitrarily
primed -PCR method. Hum Genet 102, 258–264.
[38] Dammann R, Li C, Yoon JH, Chin PL, Bates S, and Pfeifer GP
(2000 ) . Epigenetic inactivation of a RAS association domain family
protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25,
315–319.
[39] Denissenko MF, Chen JX, Tang MS, and Pfeifer GP (1997 ) . Cytosine
methylation determines hot spots of DNA damage in the human P53
gene. Proc Natl Acad Sci USA 94, 3893–3898.
[40] Eguchi K, Kanai Y, Kobayashi K, and Hirohashi S ( 1997 ) . DNA
hypermethylation at the D17S5 locus in non–small cell lung cancers: its
association with smoking history. Cancer Res 57, 4913–4915.
[41] International -Human -Genome -Sequencing -Consortium (2001 ) . In-
itial sequencing and analysis of the human genome. Nature 409, 860–
921.
[42] Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith
HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P,
Ballew RM, Huson DH, Wortman JR, Zhang Q, Kodira CD, Zheng XH,
Chen L, Skupski M, Subramanian G, Thomas PD, Zhang J, Gabor
Miklos GL, Nelson C, Broder S, Clark AG, Nadeau J, McKusick VA,
Zinder N, Levine AJ, Roberts RJ, Simon M, Slayman C, Hunkapiller M,
Bolanos R, Delcher A, Dew I, Fasulo D, Flanigan M, Florea L, Halpern
A, Hannenhalli S, Kravitz S, Levy S, Mobarry C, Reinert K, Remington
K, Abu -Threideh J, Beasley E, Biddick K, Bonazzi V, Brandon R,
Cargill M, Chandramouliswaran I, Charlab R, Chaturvedi K, Deng Z,
Francesco VD, Dunn P, Eilbeck K, Evangelista C, Gabrielian AE, Gan
W, Ge W, Gong F, Gu Z, Guan P, Heiman TJ, Higgins ME, Ji RR, Ke Z,
Ketchum KA, Lai Z, Lei Y, Li Z, Li J, Liang Y, Lin X, Lu F, Merkulov GV,
Milshina N, Moore HM, Naik AK, Narayan VA, Neelam B, Nusskern D,
Rusch DB, Salzberg S, Shao W, Shue B, Sun J, Wang ZY, Wang A,
Wang X, Wang J, Wei MH, and Wides R (2001 ) . The sequence of the
human genome. Science 5507, 1304–1351.
[43] Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, and Mao L
(2000 ) . Hypermethylation of the death - associated protein (DAP)
kinase promoter and aggressiveness in stage I non–small - cell lung
cancer. J Natl Cancer Inst 92, 1511–1516.
[44] Sato M, Mori Y, Sakurada A, Fujimura S, and Horii A (1998 ) . The H -
cadherin (CDH13 ) gene is inactivated in human lung cancer. Hum
Genet 103, 96–101.
[45] Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee
WK, Baylin SB, and Graff JR ( 1999 ) . Methylation - associated
silencing of the tissue inhibitor of metalloproteinase -3 gene suggest
a suppressor role in kidney, brain, and other human cancers. Cancer
Res 59, 798–802.
[46] Virmani AK, Rathi A, Zochbauer -Muller S, Sacchi N, Fukuyama Y,
Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, and
Gazdar AF (2000 ) . Promoter methylation and silencing of the retinoic
acid receptor -beta gene in lung carcinomas. J Natl Cancer Inst 92,
1303–1307.
[47] Esteller M, Hamilton SR, Burger PC, Baylin SB, and Herman JG
(1999 ) . Inactivation of the DNA repair gene O6 -methylguanine -DNA
methyltransferase by promoter hypermethylation is a common event in
primary human neoplasia. Cancer Res 59, 793–797.
[48] Fong KM, Kida Y, Zimmerman PV, Ikenaga M, and Smith PJ (1995 ) .
Loss of heterozygosity frequently affects chromosome 17q in non–
small cell lung cancer. Cancer Res 55, 4268–4272.
[49] Kohno T, and Yokota J ( 1999 ) . How many tumor suppressor genes
are involved in human lung carcinogenesis? Carcinogenesis 20, 1403–
1410.
[50] Nishioka M, Kohno T, Takahashi M, Niki T, Yamada T, Sone S, and
Yokota J (2000 ) . Identification of a 428 - kb homozygously deleted
region disrupting the SEZ6L gene at 22q12.1 in a lung cancer cell line.
Oncogene 19, 6251–6260.
[51] Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El -Rifai W, Hemmer S,
Huhta T, Kettunen E, Kiuru -Kuhlefelt S, Larramendy ML, Lushnikova
T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM,
Wolf M, and Zhu Y (1999 ) . DNA copy number losses in human
neoplasms. Am J Pathol 155, 683–694.
[52] Trousse F, Esteve P, and Bovolenta P (2001 ) . BMP4 Mediates
apoptotic cell death in the developing chick eye. J Neurosci 21, 1292–
1301.
322 Aberrant Methylation in Non-Small Cell Lung Cancer Dai et al.
Neoplasia . Vol. 3, No. 4, 2001
[53] Mehler MF, Mabie PC, Zhang D, and Kessler JA (1997 ) . Bone
morphogenetic proteins in the nervous system. Trends Neurosci 20,
309–317.
[54] Merino R, Ganan Y, Macias D, Rodriguez -Leon J, and Hurle JM
(1999 ) . Bone morphogenetic proteins regulate interdigital cell death in
the avian embryo. Ann NY Acad Sci 887, 120–132.
[55] Hjertner O, Hjorth -Hansen H, Borset M, Seidel C, Waage A, and
Sundan A (2001 ) . Bone morphogenetic protein - 4 inhibits proliferation
and induces apoptosis of multiple myeloma cells. Blood 97, 516–522.
[56] Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y,
Koseki T, Nishihara T, and Ikeda Y (2000 ) . Bone morphogenetic
protein - 2 induces apoptosis in human myeloma cells with modulation
of STAT3. Blood 96, 2005–2011.
[57] Tada A, Nishihara T, and Kato H (1998 ) . Bone morphogenetic protein
2 suppresses the transformed phenotype and restores actin microfila-
ments of human lung carcinoma A549 cells. Oncol Rep 5, 1137–1140.
[58] Hino J, Takao M, Takeshita N, Konno Y, Nishizawa T, Matsuo H, and
Kangawa K (1996 ) . cDNA cloning and genomic structure of human
bone morphogenetic protein -3b (Bmp -3b ) . Biochem Biophys Res
Commun 223, 304–310.
[59] Zhao R, Lawler AM, and Lee SJ (1999 ) . Characterization of GDF -10
expression patterns and null mice. Dev Biol 212, 68–79.
[60] Takao M, Hino J, Takeshita N, Konno Y, Nishizawa T, Matsuo H, and
Kangawa K (1996 ) . Identification of rat bone morphogenetic protein -
3b (BMP -3b ) , a new member of BMP -3. Biochem Biophys Res
Commun 219, 655–62.
Neoplasia . Vol. 3, No. 4, 2001
Aberrant Methylation in Non-Small Cell Lung Cancer Dai et al. 323
